Role of Glycine Metabolism in Cardiovascular Disease
甘氨酸代谢在心血管疾病中的作用
基本信息
- 批准号:9312093
- 负责人:
- 金额:$ 80.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-01 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesAnimal ModelApolipoprotein EArchitectureAtherosclerosisAttenuatedBioinformaticsBiologicalCarbamyl PhosphateCardiacCardiovascular Diagnostic TechniquesCardiovascular DiseasesCause of DeathCell AdhesionClinicalComplementDataData SetDevelopmentDietDietary SupplementationDiseaseElderlyEmployee StrikesEndocrine System DiseasesEnzymesEpidemiologyEstrogen Replacement TherapyEvaluationEventExhibitsFaceFemaleFoam CellsFoundationsFunctional disorderGeneticGenetic DeterminismGlycineGoalsGonadal Steroid HormonesHepaticHumanHuman GeneticsIncidenceInflammatoryKnowledgeLeadLesionLinkLiteratureMeasuresMedical GeneticsMeta-AnalysisMetabolismMorbidity - disease rateMusMyocardial InfarctionOutcomePathway interactionsPatientsPlasmaPopulationPredispositionPremature MenopausePrevalenceReportingRisk FactorsRoleSudden DeathSupplementationTestingVariantWomanatheroprotectivecardiovascular disorder riskcohortdietary manipulationdisease phenotypedisorder riskexperimental studygenetic analysisgenetic approachgenetic associationgenome wide association studygenome-widegenome-wide analysismRNA Expressionmacrophagemalemenmetabolomicsmortalitymouse modelnovelnovel markeroutcome forecastpopulation basedprotein expressionsexurea cycle
项目摘要
PROJECT SUMMARY
Cardiovascular Disease (CVD) is the number one cause of death for both men and women in the US.
However, the prevalence of CVD in women at advanced ages actually outnumbers men, and women generally
face a worse prognosis following a primary CVD event. Thus, there is a critical need for identifying and
understanding the sex-specific biological mechanisms that underlie the development of CVD in order to reduce
the morbidity and mortality associated with CVD, particularly in women. In this regard, our recent
metabolomics and genetic analyses in a cohort of ~10,000 CVD patients, followed by independent replication
in >53,000 subjects, led to the discovery that one of the major genetic determinants of plasma glycine levels is
strongly associated with 12% reduced risk of CVD in women (p=6.3x10-5) but not men (p=0.95). The lead
variant underlying this striking sex-specific association is located in carbamoyl phosphate synthase 1 (CPS1),
which encodes the rate-limiting enzyme in the urea cycle, and the athero-protective allele is associated with
increased glycine levels and decreased urea cycle metabolites. This novel finding represents one of the first
sexually dimorphic associations reported in the literature for CVD in either men or women, and the magnitude
of its effect is equivalent to the most strongly associated loci identified thus far for CVD. However,
epidemiological or experimental data directly linking glycine levels with CVD are lacking, and additional studies
are needed to prove that glycine metabolism is causally and inversely related to the development of
atherosclerosis. The overall goals of our application are to address these fundamentally important gaps in
knowledge. We hypothesize that glycine metabolism represents a novel sex-specific, protective, and causal
pathway for CVD. To investigate this hypothesis, we propose integrative clinical, genetics, and bioinformatics
approaches in human populations, complemented with studies that leverage targeted genetic perturbation and
dietary manipulation in animal models. In Specific Aim 1, we will determine the clinical association of glycine-
related metabolites with prevalent and incident CVD phenotypes in two independent human cohorts (n>6000),
and test whether these associations are modulated by female sex hormones. In parallel, we will conduct the
largest meta-analyses of genome-wide association study (GWAS) data to date for these metabolites
(n>12,600) and determine whether newly identified loci exhibit sex-specific associations with risk of CVD by
leveraging GWAS results from the CARDIoGRAM Consortium (n~185,000). In Specific Aim 2, we will
characterize the sex-specific metabolomics profile, atherosclerosis susceptibility, and functional/mechanistic
consequences of dietary glycine supplementation or Cps1 deficiency in mice. Taken together, the proposed
studies will leverage novel biomarker measures in independent human cohorts, already existing large-scale
GWAS data, newly developed mouse models, and ex vivo functional studies to reveal the sexually dimorphic
genetic architecture of glycine metabolism and determine its biologically causal relationship with CVD.
项目摘要
心血管疾病(CVD)是美国男性和女性的头号死因。
然而,在老年妇女中心血管疾病的患病率实际上超过了男子,妇女一般
在原发性CVD事件后面临更差的预后。因此,迫切需要查明和
了解CVD发展的性别特异性生物学机制,以减少
与心血管疾病相关的发病率和死亡率,特别是女性。在这方面,我们最近
代谢组学和遗传学分析在一个队列的约10,000名心血管疾病患者,随后独立复制
在> 53,000名受试者中,发现血浆甘氨酸水平的主要遗传决定因素之一是
与女性CVD风险降低12%(p=6.3x10-5)而非男性(p=0.95)密切相关。率先
这种显著的性别特异性关联的基础变体位于氨基甲酰磷酸合酶1(CPS 1)中,
它编码尿素循环中的限速酶,而动脉粥样硬化保护等位基因与
增加甘氨酸水平和减少尿素循环代谢物。这一新颖的发现是首批发现之一
文献中报道的男性或女性CVD的性二态性相关,
其作用相当于迄今为止对CVD鉴定的最强相关的基因座。然而,在这方面,
缺乏将甘氨酸水平与CVD直接联系起来的流行病学或实验数据,
需要证明甘氨酸代谢是因果关系和负相关的发展,
动脉粥样硬化我们的应用程序的总体目标是解决这些根本性的重要差距,
知识我们假设甘氨酸代谢代表了一种新的性别特异性,保护性和因果关系。
CVD的途径。为了研究这一假设,我们提出了整合临床,遗传学和生物信息学
在人群中的方法,辅以利用靶向遗传干扰的研究,
在动物模型中进行饮食控制。在具体目标1中,我们将确定甘氨酸的临床相关性-
在两个独立的人类组群(n>6000)中具有普遍和偶发CVD表型的相关代谢物,
并测试这些联系是否受到女性性激素的调节。与此同时,我们会进行
迄今为止,这些代谢物的全基因组关联研究(GWAS)数据的最大荟萃分析
(n> 12,600),并通过以下方法确定新鉴定的基因座是否表现出与CVD风险的性别特异性相关性:
利用来自心脏病协会的GWAS结果(n~ 185,000)。在第二阶段,我们将
表征性别特异性代谢组学特征、动脉粥样硬化易感性和功能/机制
饮食甘氨酸补充或Cps 1缺乏的后果。综合考虑,
研究将在独立的人类队列中利用新的生物标志物测量,
GWAS数据、新开发的小鼠模型和离体功能研究,以揭示性二态性
甘氨酸代谢的遗传结构,并确定其与CVD的生物因果关系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hooman Allayee其他文献
Hooman Allayee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hooman Allayee', 18)}}的其他基金
Biological Mechanisms through which TMAO Promotes Atherosclerosis
TMAO促进动脉粥样硬化的生物学机制
- 批准号:
10368090 - 财政年份:2020
- 资助金额:
$ 80.39万 - 项目类别:
Biological Mechanisms through which TMAO Promotes Atherosclerosis
TMAO促进动脉粥样硬化的生物学机制
- 批准号:
10592245 - 财政年份:2020
- 资助金额:
$ 80.39万 - 项目类别:
Nutrigenetic Intervention to Reduce Liver Fat in Hispanics
减少西班牙裔肝脏脂肪的营养遗传干预
- 批准号:
9010742 - 财政年份:2016
- 资助金额:
$ 80.39万 - 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
- 批准号:
7836973 - 财政年份:2009
- 资助金额:
$ 80.39万 - 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
- 批准号:
7643266 - 财政年份:2005
- 资助金额:
$ 80.39万 - 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
- 批准号:
7452453 - 财政年份:2005
- 资助金额:
$ 80.39万 - 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
- 批准号:
6986373 - 财政年份:2005
- 资助金额:
$ 80.39万 - 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
- 批准号:
7112247 - 财政年份:2005
- 资助金额:
$ 80.39万 - 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
- 批准号:
7279132 - 财政年份:2005
- 资助金额:
$ 80.39万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 80.39万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 80.39万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 80.39万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 80.39万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 80.39万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 80.39万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 80.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 80.39万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 80.39万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 80.39万 - 项目类别: